ClinicalTrials.gg
Not yet recruitingNCT06571214Updated Aug 27, 2024

Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment

A Phase 4 interventional study of Recombinant Human Follitropin Alfa Solution for Injection (Gonal-f®) and Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®) in Infertility, sponsored by Nanjing University. Not yet recruiting at 1 site in China. Open to female participants aged 35 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-08-27.

Sponsored by Nanjing University · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
35 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies testing follitropin alfa in Infertility — 3 open to participants now, 4 under way, 1 of them phase 3. follitropin alfa · Infertility.

Planned enrollment
6th of 30
300 · median 159
Started
2024
the only one that year
Phase 4
13 of 30
1 open now
Registered
27th of 30
by date

Among the 30 studies testing follitropin alfa in Infertility, this one is the 6th largest by planned enrollment, is the only one that started in 2024, is one of 13 in phase 4, and was the 27th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

3 of the 30 studies testing follitropin alfa in Infertility are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About follitropin alfa

follitropin alfa: first FDA approval 1997 (Gonal-f), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 35 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing follitropin alfa in Infertility, or all of them as a file.
02

Study summary

This will be an exploratory, prospective, randomized, open-label and controlled trial to evaluate the potential benefit of r-hFSH:r-hLH 2:1 co-treatment starting from COS D1 versus r-hFSH alone in patients aged 35 to 40 under ovarian stimulation treatment.

After signing informed consent form (ICF), all eligible participants will be randomly assigned in a 1:1 ratio to either treatment or control group, and GnRH antagonist protocol will be used in both treatment and control groups.

Read the detailed description

This will be an exploratory, prospective, randomized, open-label and controlled trial to evaluate the potential benefit of r-hFSH:r-hLH 2:1 co-treatment starting from COS D1 versus r-hFSH alone in patients aged 35 to 40 under ovarian stimulation treatment.

After signing informed consent form (ICF), all eligible participants will be randomly assigned in a 1:1 ratio to either treatment or control group, and GnRH antagonist protocol will be used in both treatment and control groups.

  1. Treatment group: The r-hFSH starting dose will be based on the patient's profile and physician's experience. r-hLH will be added at a ratio of 2:1 starting from day 1 of r-hFSH administration; the dose of r-hFSH during COS will be adjusted by the physician based on clinical experience and the patient's ovarian response, and the r-hFSH: r-hLH dose will be 2:1, continuing to 24\~48 hours prior to trigger drug injection.
  2. Control group: r-hFSH alone will be administrated for ovarian stimulation. The r-hFSH starting dose will be based on the patient's profile and physician's experience. The dose of r-hFSH during COS will be adjusted by the physician based on clinical experience and the patient's ovarian response, continuing to 24\~48 hours prior to trigger drug injection.

The estimated treatment duration is 11 days from the first day of COS until 24\~48 h prior to trigger drug injection, and this may vary depending on individual circumstances.

Follicular development, serum E2 and P levels will be monitored during COS according to the investigator site's ART practice until the criteria to administer trigger drug are met to induce final oocyte maturation. Trigger drug administration is to be performed according to the site's routine clinical practice.

Oocyte pick-up (OPU), IVF/ICSI, ET, and luteal phase support (LPS) will be performed according to the site's routine practice. LPS will be started after oocyte retrieval in fresh embryo transfer.

03

Conditions studied

  • Infertility

Browse trials for

Keywords

  • recombinant human LH
  • recombinant human FSH
  • ovarian stimulation treatment
  • advanced maternal age population
04

Who can participate

Ages eligible
35 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 35 to 40 (including 40)
  • 18.5\<\<28 kg/m2
  • AFC up to 14
  • First or second ART cycle
  • Planned for ovarian stimulation with GnRH-antagonist for down-regulation
  • Ejaculated sperm

Exclusion criteria

Exclusion Criteria:

  • to ART treatment
  • History of two or more spontaneous miscarriages
  • History of two or more implantation failures after fresh or frozen-warmed embryo transfers
  • Diagnosis of severe endometriosis
  • Patients with endocrine and metabolic diseases (diabetes mellitus, hypogonadotropic amenorrhea, genital system tumors, hyperprolactinemia, etc.)
  • Confirmed chromosomal abnormalities
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Treatment group

    The r-hFSH starting dose will be based on the patient's profile and physician's experience. r-hLH will be added at a ratio of 2:1 starting from day 1 of r-hFSH administration; the dose of r-hFSH during COS will be adjusted by the physician based on clinical experience and the patient's ovarian response, and the r-hFSH: r-hLH dose will be 2:1, continuing to 24\~48 hours prior to trigger drug injection. For both groups, daily injection of 0.25 mg of cetrorelix (Cetrotide®, Merck Serono S.A.) will be administrated subcutaneously when at least one follicle with diameter ≥ 14 mm or serum LH level exceeds 10 IU/L or LH level is 2 folder than basal LH level or P level exceeds 0.8 ng/ml, continuing until ovulation triggering day. Cetrorelix can be administrated earlier in patients with advanced age or diminished ovarian reserve according to judgment of clinicians.

    Drug: Recombinant Human Follitropin Alfa Solution for Injection (Gonal-f®) · Drug: Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®)

  • Active comparator
    Control group

    r-hFSH alone will be administrated for ovarian stimulation. The r-hFSH starting dose will be based on the patient's profile and physician's experience. The dose of r-hFSH during COS will be adjusted by the physician based on clinical experience and the patient's ovarian response, continuing to 24\~48 hours prior to trigger drug injection. For both groups, daily injection of 0.25 mg of cetrorelix (Cetrotide®, Merck Serono S.A.) will be administrated subcutaneously when at least one follicle with diameter ≥ 14 mm or serum LH level exceeds 10 IU/L or LH level is 2 folder than basal LH level or P level exceeds 0.8 ng/ml, continuing until ovulation triggering day. Cetrorelix can be administrated earlier in patients with advanced age or diminished ovarian reserve according to judgment of clinicians.

    Drug: Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®)

Interventions

  • DrugFollitropin alfaStudies of Follitropin alfaFollitropin alfa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    As a r-hFSH agent, Gonal-f® is used for COS. It is a prefilled ready to use pen device containing follitropin alfa for injection and is designed for subcutaneous self-administration by patients undergoing COS for ART. It is available as dose presentations of 150 IU and 450 IU. The investigators and/or his/her delegate/s will explain the use of Gonal-f® prefilled pen. Gonal-f® will be prescribed by the investigator based on clinical diagnosis and treatment routines, and will not be provided free of charge.

  • DrugRecombinant Human Lutropin alfa for Injection (r-hLH, Luveris®)

    This product is a white freeze-dried powder and a colorless and clear injection solvent, and stored away from light under 25℃ in the original packaging. Luveris® will be provided free of charge.

06

What researchers measure

Primary outcomes

  1. Good quality embryo rate (cleavage stage)

    Cleavage stage good-quality embryos are defined as embryos derived from normally fertilized zygotes with 7\~9 cells on day 3 post-fertilization, stage-specific cell size, less than 10% fragmentation, and no multinucleation. Cleavage stage good-quality embryo rate is defined as the number of cleavage stage good-quality embryos divided by the number of normally fertilized zygotes. Embryos will be assessed by two independent experienced embryologists to minimize intra-observation variability.

    Time frame: Day 3 after fertilization

Secondary outcomes

  1. Number of oocytes

    Number of oocytes is defined as the total number of oocytes obtained through transvaginal ultrasound guided puncture on the day of OPU. All follicles with an estimated diameter of ≥12 mm should be punctured.

    Time frame: 24 hours after Oocytes pick up

  2. Number of MII oocytes (analyzed in ICSI subgroup only)

    Number of MII oocyte is defined as the total number of an oocyte at metaphase of meiosis II, exhibiting the first polar body and with the ability to become fertilized

    Time frame: 24 hours after Oocytes pick up

  3. Total r-hFSH dose

    Total r-hFSH dose is defined as the total dose of r-hFSH used for subcutaneous injection during COS period.

    Time frame: 24 hours after ovulation triggering

  4. Fertilization rate

    * IVF normal fertilization rate is defined as the number of oocytes with 2PN and 2PB divided by the number of COCs inseminated. * ICSI normal fertilization rate is defined as the number of oocytes with 2PN and 2PB divided by the number of MII oocytes injected.

    Time frame: 24 hours after fertilization

  5. Blastocyst development rate

    Blastocyst development rate is defined as the proportion of blastocysts observed at 116 ± 2 h post-insemination as a function of the number of normally fertilized oocytes.

    Time frame: 5 days after fertilization, up to 7 days

  6. Utilizable embryo rate

    Utilizable embryo rate is defined as the number of embryos (or blastocysts) suitable for transfer or cryopreservation as a function of the number of normally fertilized (2PN) oocytes observed on Day 1.

    Time frame: 5 days after fertilization, up to 7 days

  7. Implantation rate

    Implantation rate is defined as the number of gestational sacs observed divided by the number of embryos transferred using transvaginal ultrasound 4\~6 weeks after embryo transfer.

    Time frame: At 4-6 weeks of amenorrhea after customized timing of embryo transfer

  8. Clinical pregnancy rate (per transfer cycle and per oocyte retrieval cycle)

    Clinical pregnancy rate is defined as the number of clinical pregnancies expressed per 100 initiated cycles, aspiration cycles, or embryo transfer cycles. Clinical pregnancy is defined as the presence of gestational sac (intrauterine or ectopic) using ultrasound examination at 4\~6 weeks after embryo transfer.

    Time frame: At 4-6 weeks of amenorrhea after customized timing of embryo transfer

  9. Ongoing pregnancy rate

    Ongoing pregnancy rate is defined as the number of intrauterine pregnancies continued for 12 gestational weeks divided by the number of embryo transfer cycles.

    Time frame: At 12 weeks of amenorrhea after customized timing of embryo transfer

  10. Ovarian sensitivity index (OSI)

    OSI is defined as the total r-hFSH dose divided by the number of oocytes retrieved.

    Time frame: 24 hours after fertilization

  11. Follicular output rate (FORT)

    FORT is defined as the number of pre-ovulatory follicles (16\~22 mm) on the day of trigger divided by the AFC (3\~8 mm)

    Time frame: 24 hours after fertilization

  12. Follicle oocyte index (FOI)

    FOI is defined as the number of total oocytes retrieved divided by the AFC

    Time frame: 24 hours after fertilization

  13. Safety Assessments

    AE, SAE and OHSS

    Time frame: During the COS cycle (average cycle range 11 days), Up to 12 weeks after transfer

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2024; primary completion for Dec 2026, 27 months later.

Of 74 non-industry phase 4 interventional studies under Infertility, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 82. This study's planned 27 months is below that.

Counting every sponsor, half of 81 studies reached it within 33 months; a quarter within 19 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2024
First posted
Aug 26, 2024
StartEst.
Sep 1, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Jan 30, 2027
Last update
Aug 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06571214
Lead sponsor
Nanjing University
Responsible party
Li-jun Ding (Director of Reproductive Medicine Department, Nanjing University) — Principal investigator
First posted
Aug 26, 2024
Start date
Sep 1, 2024 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Aug 27, 2024

Study contacts

Haixiang Sun, Dr.
Contact
stevensunz@163.com
13851622008
Haiming Xia, Dr.
principal investigator · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin alfa

Start the discussion